MedTrace Logo

Testosterone and Neurovascular Control in Humans

NCT04819204 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-03-26

No results posted yet for this study

Summary

The purpose of these studies are to evaluate the role of testosterone on autonomic and vascular function in men.

Conditions

  • Healthy

Interventions

DRUG

Cetrorelix Acetate

GnRH antagonist - subcutaneous injection. Day 1: 1-3 mg; Days 2-14: 0.25mg/daily.

DRUG

Testosterone gel

Testosterone gel - transdermal application of 5mg/day on Day 7-14 of GnRH antagonist

Sponsors & Collaborators

  • Western University, Canada

    lead OTHER

Principal Investigators

  • Joel K Shoemaker, Ph.D. · University of Western Ontario, Canada

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04819204 on ClinicalTrials.gov